Skip to main content

Jupiter Neurosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Current Price

$0.24

+16.93%
Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV
P/B
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA

Jupiter Neurosciences Inc (JUNS) Stock Chart

JUNS

JUNS Chart

Loading chart data…

JUNS Interactive Stock Chart

Interactive stock chart for Jupiter Neurosciences Inc (JUNS) with candlestick and line chart views. Analyze price action across multiple timeframes: 5 days, 1 week, 1 month, 3 months, 6 months, 1 year, 5 years, and full history.

Current price: $0.24. 52-week high: $2.97. 52-week low: $0.20. 50-day moving average: $0.37. 200-day moving average: $0.96.

Technical analysis indicators include Volume, SMA 20, SMA 50, SMA 200, EMA 20, and RSI. Toggle between candlestick and line chart styles. Overlay multiple moving averages to identify support and resistance levels, trend direction, and momentum signals for JUNS. Use the chart alongside GoodMoat's fundamental analysis tools for a complete picture of Jupiter Neurosciences Inc's investment potential.